Conmed (MEX:CNMD) ROCE %: 7.98% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CNMD Conmed Corp MEX:CNMD
80 GF Score
Price MXN720.00
GF Value MXN945.33
! 5 Warning Signs
View Full Analysis

What is Conmed ROCE %?

Conmed MEX:CNMD 80 ROCE % is 7.98% as of Jun. 2026. GuruFocus rates MEX:CNMD with a GF Score™ of 80/100 and a GF Value™ of MXN945.33. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Conmed's annualized ROCE % for the quarter that ended in Jun. 2026 was 7.98%.

Conmed  (MEX:CNMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Conmed ROCE % Related Terms

Conmed ROCE % Historical Data

* Premium members only.

The historical data trend for Conmed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conmed ROCE % Chart

Conmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.04 -2.30 5.63 10.99 4.69

Conmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.15 2.32 7.22 5.05 7.98
MEX:CNMD
80GF Score
Conmed Corp MEX:CNMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Conmed ROCE % Calculation

Conmed's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1840.255/( ( (48098.396 - 5800.596) + (41876.739 - 5672.534) )/ 2 )
=1840.255/( (42297.8+36204.205)/ 2 )
=1840.255/39251.0025
=4.69 %

Conmed's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=2738.096/( ( (41744.655 - 5278.46) + (40138.039 - 7946.257) )/ 2 )
=2738.096/( ( 36466.195 + 32191.782 )/ 2 )
=2738.096/34328.9885
=7.98 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.98% mean?
Conmed (MEX:CNMD) has a ROCE % of 7.98% as of Jun. 2026.
Is Conmed's ROCE % too high?
Conmed's current ROCE % is 7.98%. The Medical Devices & Instruments industry median ROCE % is 2.97. Conmed's value of 7.98% is 168.7% above this industry median. Overall, Conmed has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Conmed's ROCE % compare to ATEC and AORT?
Conmed's ROCE % of 7.98% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.97. Conmed's value of 7.98% is 168.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.97, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Conmed's current ROCE % of 7.98% is 168.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Conmed's current ROCE % is 7.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conmed stock overvalued right now?
Conmed (MEX:CNMD) has a current ROCE % of 7.98%. The stock's GF Value™ is MXN945.33, compared to a current price of MXN720.00 — trading 23.8% below its estimated fair value. The current ROCE % is 7.98% and 168.7% above the Medical Devices & Instruments industry median of 2.97. Conmed's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Conmed (MEX:CNMD), the current ROCE % is 7.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Conmed (MEX:CNMD) Overvalued in 2026?

Based on GuruFocus' analysis, Conmed stock appears to be undervalued. The current stock price of MXN720.00 is trading 23.8% below its estimated GF Value™ of MXN945.33.

Key valuation signals for MEX:CNMD:

  • ROCE %: 7.98%
  • GF Value™: MXN945.33 vs. price of MXN720.00 (23.8% below fair value)
  • GF Score™: 80/100 with 5 warning signs
  • Industry Position: 168.7% above the Medical Devices & Instruments median

No single metric tells the full story. See the MEX:CNMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Conmed Business Description

Other Exchanges CNMD:USA
Address 11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
80GF Score

Get the complete analysis for MEX:CNMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN720.00
Price
MXN945.33
GF Value